Aigner intelgenx

© Paracelsus Medizinische Privatuniversität | Institute of Molecular Regenerative Medicine | Ludwig Aigner

Rejuvenation of the Aged Brain

An Example of Drug Delivery in Drug Repurposing

Ludwig Aigner

IntelGenx, Grand Opening, Saint-Laurent, May 10th 2016

YESTERDAY

© Paracelsus Medizinische Privatuniversität | Institute of Molecular Regenerative Medicine | Ludwig Aigner 2

TODAY


TOMORROW


5

Age: Risk Factor Number 1

Teresa Niccoli , Linda Partridge, Ageing as a Risk Factor for Disease, Current Biology, Volume 22, Issue 17, 2012, R741 - R752

© Paracelsus Medizinische Privatuniversität | Institute of Molecular Regenerative Medicine | Ludwig Aigner


Massive Increase in the Prevalence of AD


GeneticNon-Genetic

Alt


Alzheimer Pathology


Are We Targeting the Right Thing ?

Rodrigue et al., Neuropsychol Rev. 2009


1001 Reasons for Neuronal Cell Death ???


Neurodegenerationeg Schapira et al. 2011

Neuroinflammationeg Hirsch et al. 2009

Blood Brain Barriereg Zlokovic et al. 2008

Neurogenesiseg Regensburger et al. 2014

Neurotransmissioneg Calabresi et al. 2007

Our Targets:

Pleiotropic Signaling

Demyelination

Axonal Damage

eg Franklin et al. 2008


AGING and REJUVENATION







Demyelination

Axonal Damage


The Aged Brain is a „Diseased“ Brain

Regeneration

Disease RiskDisease Risk

Live = Aging

Growth Plasticity Degeneration Disease


Growth Plasticity Degeneration

Aging and Rejuvenation

„Regenerative Pharmacology“

Disease



Can We Turn Back the Clock ?


Muscle Research, Aging, and Regenerative Medicine ?


inflammation

neurogenesis

cognitiion

Modulating the Systemic Milieu: a Valid Approach


Eotaxin Reduces Neurogenesis

Eotaxin Worsens Cognition

Old Blood Contributes to Brain Aging

EOTAXIN


Eotaxin Leukotrienes

Allergy / Asthma Brain Aging

Aging / Degeneration


Leukotrienes Impact on Brain Aging

Leukotrienes






Demyelination

Axonal Damage


Monte

lukast

Proof of Principle:

Inhibition of Leukotriene Receptors Improves Cognition in Aged Rats


symptoms pathology therapy

motoric dopaminergic cell loss dopamine replacement

60%

Parkinson´s Disease Dementia / Lewy Body Dementia

symptoms pathology therapy

motoric dopaminergic cell loss dopamine replacement

dementia ??? rivastigmine

Neurogenesis

Blood Brain Barrier

Neuroinflammation

Neurodegeneration

Neurotransmission

eg Schapira et al. 2011

eg Hirsch et al. 2009

eg Zlokovic et al. 2008

eg Regensburger et al. 2014

eg Calabresi et al. 2007


**

Learning Memory

*

Montelukast Improves Cognitive Functions in PD / LBD Animals



1 1 2 2 1 1 2 3 3 4 3 2 2 4 4 2 3 3 6 7 6 11 714

7 13 15 12 15 19 17 23 25

50 48

99

126

239

317

414

0

50

100

150

200

250

300

350

400

450

19

73

19

75

19

76

19

77

19

78

19

79

19

80

19

82

19

83

19

85

19

86

19

87

19

88

19

89

19

90

19

91

19

92

19

93

19

94

19

95

19

96

19

97

19

98

19

99

20

00

20

01

20

02

20

03

20

04

20

05

20

06

20

07

20

08

20

09

20

10

20

11

20

12

20

13

20

14

20

15

Nu

mb

er

of

Pu

blic

ati

on

sAnnual Counts of Publications “Drug Repurposing”


“All De- and Regenerations are Similar”


REPAIR

REPLACE

RESTORE

REGENERATE

REJUVENATE

Regenerative Medicine

All Organs

Different Diseases


MMSE 13: moderate to severe dementia

Montelukast as an Anti-Dementia Therapeutic

Before After 2 Months of Montelukast

MMSE 22: mild dementia


Discover

y

Preclini

c

Phase

I

Phase

II

Phase

III

Approval

BIOTECH

Academia Big Pharma


Let‘s make a better Montelukast

Aigner intelgenx

Healthcare

Transcript of Aigner intelgenx